UNSPSC 51292601: Clorazepate

This classification denotes an anti-anxiety agent, anticonvulsant, and gaba modulator with the molecular formula C16H11ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D51WO0G0L4, chemically known as 7-chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1h-1,4-benzodiazepine-3-carboxylic acid but generally known as clorazepate, which bears US NIH Compound Identifier 2809. Most nations schedule clorazepate under HS 29339100 and SITC 51577. SMILES: C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)CL)C(=O)O.

UNSPSC 51292601 Clorazepate is a Commodity code covering pharmaceutical products in the benzodiazepine family, yet recent state and local procurement activity under this code does not reflect purchases of clorazepate itself. Instead, the only recent opportunity tagged to this code involves naloxone (an opioid antagonist) and drug deactivation systems—products entirely outside the scope of the nominal code category. State and local governments solicit pharmaceutical supplies through various issuing bodies including county health departments and community health agencies, typically via IFB or RFQ when procuring medical consumables and controlled substances. The typical work involves purchasing FDA-approved medications, vaccines, and related medical products for public health programs, emergency response, and community clinics, with compliance requirements including drug-free workplace certification, E-Verify authorization, workers' compensation and liability insurance, and federal environmental and procurement regulations when federal funding applies.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building at 520 W. Lake Mary Blvd in Sanford, Florida. The contract carries a two-year initial term with an optional one-year renewal and includes a three-month probationary period. However, the singular recent opportunity and the substantial mismatch between the code's nominal pharmaceutical category and the naloxone/deactivation-system procurement suggest this code shows minimal relevant activity in current state and local procurement. Firms pursuing benzodiazepine pharmaceutical supply contracts should track activity under broader pharmaceutical or medical supply codes rather than relying on this commodity classification.